Hole in one: CD137-ADC eliminates GVHD

Nierkens S, Lindemans CA (2025) Hole in one: CD137-ADC eliminates GVHD. Blood 146(9):1038-1040. doi: 10.1182/blood.2025029867 PMID: 40875553

Objective: To show that a single dose of CD137-ADC can prevent acute graft-versus-host disease (GVHD) while pre-serving immune reconstitution in a nonhuman primate (NHP) model of stem cell transplantation.

Summary: Results showed that animals treated with CD137-ADC exhibited markedly reduced clinical and histopathological features of GVHD, improved survival, and, notably, no need for additional immunosuppressive therapy. Although still in preclinical development, these findings support the potential for translation to highly needed human therapy.

Related Products: Saporin (Cat. #PR-01)

See Also:

• Gerdemann U, Kimler K, Warren MR, McGuckin C, Fleming RA, D’Ambra MR, Eran A, Albanese A, Chen E, Winschel MB, Cagnin L, Lane J, Gorfinkel L, Adams BW, Kwun J, Lanieri L, Hoban MD, Lamothe TL, Hyzy SL, Olson LM, Panoskaltsis-Mortari A, Prockop SE, Blazar BR, Kean LS, Tkachev V (2025) A single dose of a CD137 antibody-drug conjugate protects nonhuman primate allogeneic HCT recipients against acute GVHD. Blood blood.2024027239. doi: 10.1182/blood.2024027239 PMID: 40504994